Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of XEN-101 in Healthy Volunteers
NCT05667129Phase 1Completed
- Sponsor
- Xeno Biosciences
- Start
- Dec 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing XEN-101 with Placebo (2 arms). Primary endpoint: Frequency of adverse events. Started Dec 2022; status: completed.
02
Drugs
XEN-101
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05667129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05667129.